Good morning :)
$
₹
Spyre Therapeutics Inc.

Spyre Therapeutics Inc.

SYRE

NASDAQ
Asset Logo

Spyre Therapeutics Inc.

SYRE

NASDAQ
$99.150.11% (-0.11)
$
₹
$99.150.11% (-0.11)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $8.9B the stock is ranked 1036

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

9.44
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.9
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 18 analysts reports

Buy
17 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+23.52%

Earnings Growth

-44.09%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 23.52% growth, versus a trailing 3-year CAGR of 109.96%.

2026
Current$99.04Baseline
Analyst Target - 1 year
Target$122.33+23.52%

All values in $

202220232024202520262027$41.23$72.34$103.45Target+23.52%
2026
Current$99.04Baseline
Analyst Target - 1 year
Target$122.33+23.52%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.98Baseline
Forecast for Dec 2026
High$-2.37-19.7%
Average$-2.85-44.09%
Low$-4.81-142.93%

All values in $

202120222023202420252026-25-25.75-75.14-4.23-1.98Low-142.93%Average-44.09%High-19.7%
2025
Current$-1.98Baseline
Forecast for Dec 2026
High$-2.37-19.7%
Average$-2.85-44.09%
Low$-4.81-142.93%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-11.1
90.4
-62.5
-69
-36.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue000000090.4900
Net Income-43.85-38.83-69.02-56.29-44.77-36.71-11.18-62.53-69-36.2
Net Profit Margin--------69.09%--
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Spyre Therapeutics Inc. -9.44-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SYRE with any stock or ETF
Compare SYRE with any stock or ETF
Comparing from
SYRE
ABBV
AMGN
Loading...

Frequently asked questions

  1. Spyre Therapeutics Inc. (SYRE) share price today is $99.15 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $99.15 and a day low of $92.99.

  2. Spyre Therapeutics Inc. stock trades on NASDAQ under the ticker symbol SYRE.

  3. Spyre Therapeutics Inc.'s market capitalization is $8.92B as of November 5, 2026 at 2:29 AM IST.

  4. Spyre Therapeutics Inc.'s price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Spyre Therapeutics Inc.'s price-to-book (P/B) ratio is 9.44 as of November 4, 2026.

  6. Yes, You can buy Spyre Therapeutics Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Spyre Therapeutics Inc. shares in three steps: 1. Search Spyre Therapeutics Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Spyre Therapeutics Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Spyre Therapeutics Inc. (SYRE) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1008 shares at the current price of $99.15.

Loading...